In this thesis, our objective is to improve the energy efficiency and load balance for wireless networks. We first study the relationships between the base station (BS) on/off operation and traffic distribution. A cooperative power saving method called clustering BS-off (CBSO) scheme is proposed. Instead of adopting a unified and consistent BS-off scheme in the whole network, the proposed centralized and distributed CBSO schemes can adaptively group BSs in several clusters based on the traffic fluctuations with space and time. Second, to further improve the network load balance and energy efficiency in distributed manner, we propose a power efficient self-organized virtual small networking (VSN) protocol. A heuristic firefly algorithm is applied to arrange the BSs' operation in small groups based on the traffic level. By jointly considering the load balance, the effectiveness of the proposed algorithm is demonstrated based on the average and min-max traffic levels of BSs' groups. Finally, the importance of detailed BS operation between active and sleep modes is considered. The operating procedure of femtocell base station, i.e., HeNB, is modeled as an MAP/PH/1/k queueing system. Such queueing analysis particularly focuses on the HeNB vacation process with user priorities. The HeNB's power on/off scheme is modeled as alternative service and vacation periods. The hybrid access is regarded as high and low priority users in the queuing system. We further propose the adaptive service rate and vacation length (ASV) method, so that the HeNB can work in a more energy-efficient way while satisfying QoS requirements such as blocking probability and users waiting time. Simulation results show the effectiveness of the proposed strategies and the overall network energy efficiency can be improved significantly. / October 2016

Nós avaliamos a utilidade de um painel de anticorpos constituído por CD5, CD10, CD23, CD43, bcl-2 e ciclina D1 na classificação de 134 linfomas de pequenas células B. O CD10, positivo nos linfomas foliculares, o CD23, positivo nos linfomas linfocíticos/LLC, e a ciclina D1, expressa nos linfoma do manto, foram os que mais contribuíram na diferenciação destes linfomas, firmando o diagnóstico em 88,1% dos casos. A ausência de aspecto nodular e de células dendríticas, e a presença de centros de proliferação diferencia o linfoma linfocítico/LLC dos outros tipos. A expressão de proteína p53 e de antígeno Ki-67 > 20% foi associada com tempo de sobrevida menor, principalmente no linfoma do manto / We evaluated the usefulness of a panel of antibodies comprising CD5, CD10, CD23, CD43, bcl-2 and cyclin D1 in the classification of 134 small B-cell lymphomas. CD10, positive in follicular lymphomas, CD23, positive in lymphocytic lymphoma/CLL and cyclin D1 expressed in mantle cell lymphoma were the ones that contributed the most in the differentiation of these lymphomas, confirming the diagnosis in 88.1% of the cases. The absence of nodular aspect and dendritic cells and the presence of proliferation centers differentiate the lymphocytic lymphoma/CLL from the other types. The expression of p53 protein and Ki-67 > 20% was associated to a shorter survival, especially in mantle cell lymphoma

Ping Zhang. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (p. 131-144). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

Nós avaliamos a utilidade de um painel de anticorpos constituído por CD5, CD10, CD23, CD43, bcl-2 e ciclina D1 na classificação de 134 linfomas de pequenas células B. O CD10, positivo nos linfomas foliculares, o CD23, positivo nos linfomas linfocíticos/LLC, e a ciclina D1, expressa nos linfoma do manto, foram os que mais contribuíram na diferenciação destes linfomas, firmando o diagnóstico em 88,1% dos casos. A ausência de aspecto nodular e de células dendríticas, e a presença de centros de proliferação diferencia o linfoma linfocítico/LLC dos outros tipos. A expressão de proteína p53 e de antígeno Ki-67 > 20% foi associada com tempo de sobrevida menor, principalmente no linfoma do manto / We evaluated the usefulness of a panel of antibodies comprising CD5, CD10, CD23, CD43, bcl-2 and cyclin D1 in the classification of 134 small B-cell lymphomas. CD10, positive in follicular lymphomas, CD23, positive in lymphocytic lymphoma/CLL and cyclin D1 expressed in mantle cell lymphoma were the ones that contributed the most in the differentiation of these lymphomas, confirming the diagnosis in 88.1% of the cases. The absence of nodular aspect and dendritic cells and the presence of proliferation centers differentiate the lymphocytic lymphoma/CLL from the other types. The expression of p53 protein and Ki-67 > 20% was associated to a shorter survival, especially in mantle cell lymphoma

Yung, Kam Fai. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2009. / Includes bibliographical references (leaves 107-129). / Abstracts in English and Chinese. / ABSTRACT --- p.ii / 摘要 --- p.iv / ACKNOWLEDGEMENTS --- p.vi / TABLE OF CONTENTS --- p.vii / PUBLICATION --- p.ix / LIST OF TABLES --- p.x / LIST OF FIGURES --- p.xi / LIST OF ABBREVIATIONS --- p.xii / Chapter SECTION I: --- BACKGROUND --- p.1 / Chapter CHAPTER 1: --- "The biology, diagnostics and management of lung cancer" --- p.2 / Chapter 1.1 --- "Basic biology, classification and diagnostics" --- p.2 / Chapter 1.1.1 --- Epidemiology and etiology of lung cancer --- p.2 / Chapter 1.1.2 --- Clinical Presentation and Diagnostics of Lung Cancer --- p.3 / Chapter 1.2 --- Treatment of lung cancer --- p.9 / Chapter 1.2.2 --- Radiotherapy --- p.10 / Chapter 1.2.3 --- Chemotherapy --- p.11 / Chapter CHAPTER 2: --- Epidermal Growth Factor Receptor Mutations in Lung Cancer --- p.13 / Chapter 2.1 --- The Epidermal Growth Factor Receptor --- p.13 / Chapter 2.2 --- Overexpression of EGFR in NSCLC --- p.14 / Chapter 2.3 --- The development of EGFR inhibitors --- p.15 / Chapter 2.3.1 --- Monoclonal Antibodies --- p.16 / Chapter 2.3.2 --- Small-molecule inhibitors --- p.17 / Chapter 2.3.2.1 --- Gefitinib --- p.17 / Chapter 2.3.2.2 --- Erlotinib --- p.19 / Chapter 2.3.2.3 --- Other small-molecule inhibitors --- p.20 / Chapter 2.4 --- Mutations of EGFR in NSCLC --- p.21 / Chapter 2.4.1 --- Activating Mutations conferring sensitivity to tyrosine kinase inhibitors --- p.21 / Chapter 2.4.2 --- Secondary mutations associated with resistance to tyrosine kinase inhibitors --- p.23 / Chapter 2.5 --- EGFR gene amplification --- p.24 / Chapter 2.6 --- Detection of EGFR mutations --- p.25 / Chapter 2.7 --- Aim of the thesis --- p.31 / Chapter SECTION II: --- DETECTION OF EGFR MUTATIONS IN TUMOR AND PLASMA SAMPLES BY MASS SPECTROMETRY AND DIGITAL PCR --- p.33 / Chapter CHAPTER 3: --- Detection of EGFR mutations by mass spectrometric methods --- p.34 / Chapter 3.1 --- Introduction --- p.34 / Chapter 3.1.1 --- Principles of Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) --- p.34 / Chapter 3.1.2 --- The MassARRAY Homogenous MassEXTEND (hME) assay --- p.35 / Chapter 3.1.3 --- The Single-Allele Base Extension Reaction (SABER) and the Allele-Specific Base Extension Reaction (ASBER) --- p.36 / Chapter 3.2 --- Materials and Methods --- p.36 / Chapter 3.2.1 --- The protocol for the detection of EGFR exon 21 point mutation by Mass Spectrometric Methods --- p.37 / Chapter 3.3 --- Results --- p.42 / Chapter 3.4 --- Discussion --- p.49 / Chapter CHAPTER 4: --- Evaluation of the detection limit and sensitivity of the digital PCR assays --- p.51 / Chapter 4.1 --- Introduction --- p.51 / Chapter 4.1.1 --- The theoretical basis of digital PCR quantification and the relationship with the Poisson distribution --- p.51 / Chapter 4.1.2 --- Assessment of Assay Detection Limit --- p.54 / Chapter 4.1.3 --- Comparing Digital PCR with sequencing after conformation sensitive gel electrophoresis (CSGE) --- p.59 / Chapter 4.2 --- Materials and Methods --- p.59 / Chapter 4.2.1 --- Design of digital PCR assay for the detection of EGFR exon21 L858R point mutation --- p.59 / Chapter 4.2.2 --- Design of digital PCR assay for the detection of EGFR exon19 deletion --- p.60 / Chapter 4.2.3 --- The protocols of digital PCR assays for EGFR mutation detection --- p.64 / Chapter 4.2.4 --- Single molecule detection test --- p.65 / Chapter 4.2.5 --- Artificial mixtures of mutant and wild-type DNA --- p.66 / Chapter 4.2.6 --- Sequencing after CSGE --- p.66 / Chapter 4.3 --- Results --- p.67 / Chapter 4.3.1 --- Results of the single molecule detection test and artificial mixture analysis --- p.67 / Chapter 4.3.2 --- Results of CSGE and sequencing compared with digital PCR --- p.73 / Chapter 4.4 --- Discussion --- p.75 / Chapter CHAPTER 5: --- Detection of EGFR mutations in prospectively collected tumor samples of NSCLC patients --- p.77 / Chapter 5.1 --- Introduction --- p.77 / Chapter 5.2 --- Materials and Methods --- p.78 / Chapter 5.2.1 --- Sample preparation and DNA extraction of tumor tissues --- p.78 / Chapter 5.3 --- Results --- p.79 / Chapter 5.4 --- Discussion --- p.82 / Chapter CHAPTER 6: --- Detection of EGFR mutations in prospectively collected plasma samples of NSCLC patients --- p.85 / Chapter 6.1 --- Introduction --- p.85 / Chapter 6.2 --- Materials and Methods --- p.87 / Chapter 6.2.1 --- Sample preparation and DNA extraction of plasma samples --- p.87 / Chapter 6.3 --- Results --- p.88 / Chapter 6.3.1 --- Digital PCR analysis of EGFR mutations in plasma samples of NSCLC patient --- p.88 / Chapter 6.3.2 --- Variations in plasma EGFR mutation concentration after TKI treatment --- p.93 / Chapter 6.4 --- Discussion --- p.96 / Chapter SECTION III: --- CONCLUDING REMARKS --- p.100 / Chapter CHAPTER 7: --- Conclusion and future perspectives --- p.101 / Chapter 7.1 --- Mass spectrometric analysis --- p.101 / Chapter 7.2 --- Microfluidics Digital PCR --- p.102 / Chapter 7.3 --- Future perspectives --- p.105 / References --- p.107

No description available.

Non-Small-Cell-Lung Cancer (NSCLC) patients with mutations in EGFR have greater response rates and survival when treated with the tyrosine kinase inhibitor erlotinib. To elucidate how erlotinib inhibits EGFR, this study included: 1) inhibiting an EGFR mutant cell line to reveal EGFR regulated phosphotyrosine (pY) sites; 2) comparing erlotinib sensitive and insensitive cell lines to reveal functionally important pY sites; 3) revealing novel pY sites. Observations were collected using the LTQ-Orbitrap mass spectrometer. This study identified five new EGFR regulated pY sites and five pY sites that correlated with erlotinib sensitivity; the majority of them are related to cell-cell interactions. By comparing all observed pY sites to the Phosphosite and PhosphoELM database, our results included 67 unregistered sites. This study has identified novel biomarkers and potential therapeutic targets, many of which were associated with cell migration and adhesion function. Further functional validation is necessary.

Non-Small-Cell-Lung Cancer (NSCLC) patients with mutations in EGFR have greater response rates and survival when treated with the tyrosine kinase inhibitor erlotinib. To elucidate how erlotinib inhibits EGFR, this study included: 1) inhibiting an EGFR mutant cell line to reveal EGFR regulated phosphotyrosine (pY) sites; 2) comparing erlotinib sensitive and insensitive cell lines to reveal functionally important pY sites; 3) revealing novel pY sites. Observations were collected using the LTQ-Orbitrap mass spectrometer. This study identified five new EGFR regulated pY sites and five pY sites that correlated with erlotinib sensitivity; the majority of them are related to cell-cell interactions. By comparing all observed pY sites to the Phosphosite and PhosphoELM database, our results included 67 unregistered sites. This study has identified novel biomarkers and potential therapeutic targets, many of which were associated with cell migration and adhesion function. Further functional validation is necessary.

Thesis (Ph. D.)--University of Nevada, Reno, 1999. / Includes bibliographical references. Online version available on the World Wide Web.

Yearly, 22, 200 Canadians are diagnosed with lung cancer, with 80-85% of the cases being non-small cell lung cancer (NSCLC). With diagnoses being predominantly in the advanced stages, prognosis is poor and quality of life (QoL) becomes the focus of treatment. The main symptom cachexia, issues a loss of strength and impacts on an important aspect of QoL, physical function. Physical function is predominately assessed subjectively. Lately performance-based measures are gaining in popularity. One performance measure, the chair rise test, has not been validated in the NSCLC population and was the objective of this study. / Subjects completed the chair rise test, 6MWT, hand grip, and the SF-36 pre and post chemotherapy. Evidence for construct and discriminant validity but not predictive validity was provided for the chair rise test. The 60-second chair rise may be too strenuous for persons with severe disability but a standardized timed-based chair rise test is needed.